Capivasertib API Manufacturers & Suppliers

Capivasertib (CAS Number 1143532-39-1) is an orally bioavailable pan-AKT kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication specifically targets patients whose tumors harbor one or more alterations in PIK3CA, AKT1, or PTEN genes, as identified by an FDA-approved test, following progression on at least one prior endocrine-based regimen in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.

The pharmacological rationale for capivasertib centers on its inhibition of all three isoforms of AKT (AKT1, AKT2, AKT3), key serine/threonine kinases within the PI3K/AKT signaling pathway. Hyperactivation of this pathway is a common driver of breast cancer progression due to mutations in AKT1, loss of function mutations in the tumor suppressor PTEN, or activating mutations in PIK3CA. Capivasertib acts by inhibiting phosphorylation of downstream AKT substrates, resulting in reduced cellular proliferation and tumor growth. Preclinical studies demonstrated dose-dependent inhibition of breast cancer cell lines with relevant genetic alterations and tumor growth retardation in xenograft models.

Pharmacokinetic and pharmacodynamic relationships have been partially characterized. Dose-dependent adverse events including diarrhea, rash, and hyperglycemia have been associated with capivasertib exposure at doses up to 800 mg, exceeding the approved dose. Notably, at the recommended therapeutic dosage, no clinically significant prolongation of QTc interval (›20 ms) has been observed. Capivasertib is a substrate for cytochrome P450 enzymes, notably CYP3A4, and is known to inhibit multiple drug transporters including BCRP/ABCG2, MATE1/2, OAT3, OATP1B1/1B3, and OCT2, which implicates potential drug-drug interaction considerations.

Safety evaluation highlights common adverse effects related to its mechanism on metabolic and dermatologic pathways. The drug’s approval followed positive clinical outcomes in the CAPItello-291 trial, where capivasertib combined with fulvestrant conferred a significant reduction in disease progression risk compared to fulvestrant alone in the targeted patient population.

From an API procurement perspective, capivasertib's complex molecular structure as an alpha amino acid amide derivative necessitates stringent analytical characterization and compliance with regulatory standards for identity, purity, and batch-to-batch consistency. Given its status as a substrate and inhibitor of major metabolic enzymes and transporters, high-quality API sourcing and thorough impurity profiling are critical to minimize variability in pharmacokinetics and ensure patient safety in combination therapies.